News
Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...
Investor's Business Daily on MSN5d
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal?
Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...
Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a ...
Exact Sciences delivered a quarter characterized by strong year-over-year revenue growth and margin improvement, but the ...
The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...
Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...
Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...
Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value ...
Exact Sciences’ gross margin for the quarter was 69%, with adjusted gross margin at 72%. The company reported operating cash flow of $89 million and free cash flow of $47 million, ending the quarter ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback